Tariffs on Pharma

TL;DR

• Tariffs are coming: The U.S. is considering pharmaceutical tariffs of 15% on EU imports and up to 250% on branded drugs.

• Mid-market pharma is most at risk: Companies relying on global suppliers face disruption, tighter margins, and possible R&D cuts.

• Critical exemptions exist: Generic drugs and their APIs may be excluded, helping protect affordability.

• Proactive planning is now essential: Companies must map exposure, run cost scenarios, and build buffer inventory.

• Agility is a competitive edge: Dynamic, integrated planning software helps manage tariff risk, protect supply continuity, and stay compliant in a volatile trade environment.

Tariffs on Pharma and What it Means for Your Supply Chain

The potential imposition of sweeping pharmaceutical tariffs by the Trump administration represents one of the most significant shifts in global healthcare trade policy in decades.

For mid-market pharmaceutical companies, which often rely on tightly managed, multi-jurisdictional supply networks, understanding this policy and its core economic incentives is crucial for maintaining stability, controlling costs, and ensuring continued product availability.

The discussion, framed around domestic manufacturing and national security, moves away from the historical practice of allowing most pharmaceutical products to enter the United States duty-free.

The Two-Tiered Tariff Structure Under Consideration

While the overall goal of the policy is to encourage reshoring of manufacturing, the proposed tariffs are taking shape in two distinct tiers, with different rates and target regions.

The US-EU Framework (15% Ceiling)

Based on a recent trade deal framework, the US and the European Union have agreed to a 15% tariff ceiling on a category of goods, which includes pharmaceuticals from the EU bloc. This is considered a cap, ensuring that potential tariffs from other mechanisms, such as those arising from an ongoing investigation under Section 232 of the Trade Expansion Act, will not exceed this rate for EU exports.

Critically, the agreement provides exemptions for certain essential products, including generic drugs and their active pharmaceutical ingredients (APIs). This distinction is vital for maintaining the affordability of widely used prescription drugs.

The Domestic Production Incentive (100% to 250%)

The most dramatic proposal comes in the form of extremely high tariffs - sometimes floated as high as 100% or even 250% - on tariff imported expensive branded or patented medicines. The stated intent is not to collect revenue, but to compel drug manufacturers to build new production plants in the United States. The tariffs would be phased in, often with a grace period of 12 to 18 months, allowing companies time to break ground on domestic manufacturing facilities to achieve an exemption.

Industry Implications for Mid-Market Pharma

The industry's reaction has been one of concern, particularly regarding the potential for supply disruption and increased costs. For mid-market companies that are often the backbone of the generic drugs market, the volatility is especially threatening.

The key risks include:

1. Supply Chain Disruption: Pharmaceutical supply chains are among the world's most complex, often spanning three or more continents for a single drug product. Tariffs on intermediate materials or finished products, even at the lower 15% rate, disrupt these carefully costed models. This complexity increases the risk of drug shortages, which negatively impacts public health.

2. Margin Compression for Generics: Generic companies operate on extremely tight margins. Unlike expensive branded products, they cannot easily absorb a significant tariff on pharma without passing the full cost on to consumers or, worse, deciding to exit the market for a specific drug. Given that generics account for the majority of prescriptions filled in the U.S., the impact of these decisions on access and drug prices is significant.

3. Diverted Investment from R&D: The European Federation of Pharmaceutical Industries and Associations (EFPIA) has suggested the cost of the tariffs could divert billions of dollars that would otherwise be invested in research and development (R&D) for new treatments.

The Urgent Need for Planning and Agile Sourcing

The potential tariffs are forcing pharmaceutical companies to engage in rapid, high-stakes supply chain remodeling. This is where the core challenge for many mid-market firms lies.

Companies that have historically relied on simplified planning (such as using disconnected Excel spreadsheets or legacy tools for forecasting and sourcing) are suddenly facing a crisis. They must quickly be able to:

1. Map True Exposure: Accurately trace every active pharmaceutical ingredient (API) and intermediate drug product back to its country of origin to determine its precise tariff exposure.

2. Model Scenarios: Run complex simulations comparing the Total Landed Cost (TLC) of:

• Paying the 15% pharmaceutical import duty.

• Absorbing a 100%+ tariff.

• Making the multi-year capital investment to move manufacturing to the U.S.

3. Ensure Inventory Buffer: Calculate the necessary buffer stock to prevent drug shortages during the transition period or in the event of unforeseen tariff implementation dates.

Moving away from fragmented, rigid planning is not just about efficiency. It is a mandatory step for navigating this uncertain trade environment and maintaining competitive viability.

Navigating Future Uncertainty

The specter of high pharmaceutical tariffs underscores the administration’s focus on supply chains as a component of national security. While the policy aims to boost domestic manufacturing, the industry must prepare for short-term disruption. Agility in supply chain planning and the ability to instantly model cost impacts across diverse drug product portfolios will be essential tools for mid-market companies determining how to manage drug prices and meet their obligations to patients.

FAQs

1. How could U.S. pharmaceutical tariffs impact mid-market pharma supply chains?

Proposed tariffs, including 15% on EU imports and up to 100–250% on branded medicines, pose significant challenges for mid-market pharmaceutical companies. These tariffs can disrupt global supply chains, increase costs, and create risks of drug shortages, particularly for companies reliant on multi-continent sourcing of APIs and intermediates.

2. Which pharmaceutical products are likely to be exempt from tariffs?

Essential generics and their active pharmaceutical ingredients (APIs) are generally exempt under frameworks like the US-EU agreement. These exemptions help ensure critical medications remain affordable and accessible, minimizing the risk of disruption to public health.

3. What are the key risks of tariffs for mid-market pharma companies?

Tariffs can compress margins for generics, divert investment from R&D, and force operational adjustments across supply chains. Even moderate tariffs can trigger price increases, potential market exits for specific drugs, and increased logistical complexity due to multi-jurisdictional sourcing.

4. How can companies mitigate tariff risks and maintain supply chain stability?

Mid-market pharmaceutical companies can take proactive steps such as mapping tariff exposure across all APIs and intermediates, modeling total landed costs for different scenarios, investing in buffer stock to prevent shortages, and exploring agile sourcing or domestic manufacturing options to reduce dependency on high-tariff imports.

5. Why is agile supply chain planning critical in a high-tariff environment?

Agility allows companies to respond quickly to policy changes, optimize costs, and maintain service levels. Real-time scenario modeling, dynamic demand forecasting, and flexible procurement strategies enable mid-market pharma companies to anticipate disruptions, safeguard patient supply, and stay compliant with regulatory requirements.

6. Can mid-market companies benefit from domestic production to reduce tariff exposure?

Yes. High proposed tariffs are intended to incentivize reshoring of pharmaceutical manufacturing. Companies can weigh the costs of establishing domestic production facilities against tariff payments, using scenario planning to make strategic decisions that balance short-term cost with long-term supply security.

7. How does integrated planning software support tariff management and risk mitigation?

Modern planning solutions consolidate global supply chain data, automate cost modeling, and simulate multiple “what-if” scenarios. These tools help companies evaluate tariff impacts, optimize inventory, coordinate production across sites, and maintain compliance, reducing both financial and operational risks in a volatile trade environment.